Overview

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

Status:
Completed

Trial end date:
2020-03-05

Target enrollment:

Participant gender:

Summary

To compare the efficacy of pegilodecakin in combination with FOLFOX versus FOLFOX alone in participants with metastatic pancreatic cancer as measured by overall survival.

Phase:

Phase 3

Details

Lead Sponsor:

ARMO BioSciences
Eli Lilly and Company

Collaborator:

ARMO BioSciences

Treatments:

Leucovorin
Oxaliplatin